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Background. Reliable on-site polymerase chain reaction (PCR) testing for Marburg hemorrhagic fever (MHF)
is not always available. Therefore, clinicians triage patients on the basis of presenting symptoms and contacthistory.
Using patient data collected in Uige, Angola, in 2005, we assessed the sensitivity and speciﬁcity of these factors
to evaluate the validity of World Health Organization (WHO)–recommended case deﬁnitions for MHF.
Methods. Multivariable logistic regression was used to identify independent predictors of PCR conﬁrmation
of MHF. A data-derived algorithm was developed to obtain new MHF case deﬁnitions with improved sensitivity
and speciﬁcity.
Results. A MHF case deﬁnition comprising (1) an epidemiological link or (2) the combination of myalgia or
arthralgia and any hemorrhage could potentially serve as an alternative to current case deﬁnitions. Our data-
derived case deﬁnitions maintained the sensitivity and improved the speciﬁcity of current WHO-recommended
case deﬁnitions.
Conclusions. Continued efforts to improve clinical documentation during ﬁlovirus outbreaks would aid in
the reﬁnement of case deﬁnitions and facilitate outbreak control.
Marburg hemorrhagic fever (MHF) was ﬁrst described
in 1967 in an outbreak in Germany and the former
Yugoslavia that was linked to contact with monkeys
imported from Uganda [1]. The causative agent of
MHF is Lake Victoria marburgvirus (MARV), a ﬁlovirus
similar to Ebola virus [2]. Disease onset is sudden, with
fever, chills, headache, and myalgia. Approximately 5
days after disease onset, a nonpruritic rash may appear,
followed by nausea, vomiting, diarrhea, bone pain, and
abdominal pain. Symptoms may become increasingly
severe and lead to massive hemorrhaging and mul-
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tiorgan dysfunction [3]. Most deaths occur during the
second week of illness [4]. Person-to-person transmis-
sion occurs through direct contact with symptomatic
patients with MHF, their body ﬂuids, or their remains
[4]. The natural reservoir of the virus remains un-
known, although bats have been implicated [5, 6].
Since 1967, sporadic cases of MHF [7–12] and2 large
outbreaks have been recorded [3, 13]. The 1998–2000
outbreak occurred in the Durba and Watsa region of
the Democratic Republic of the Congo, resulting in 154
cases and 125 deaths (case–fatality rate [CFR], 83%)
[14, 15]. The 2005 outbreak occurred in Uige, Angola,
with 374 putative cases (including 158 laboratory-con-
ﬁrmed cases) and 329 deaths (CFR, 88%) [16]. The
relatively low number of recognized infections and the
poor quality of their clinical documentation [17] have
hampered the assessment of clinical MHF character-
istics in humans.
Diagnostic tests for MHF include reverse-transcrip-
tase polymerase chain reaction (PCR) assays to identify
viral nucleic acids [18]. However,theusefulnessofthese
assays is limited during the ﬁrst few days of illness
because of low concentrations of circulating virus [19,1910 • JID 2010:201 (15 June) • Roddy et al
Figure 1. Uige Provincial Hospital’s Marburg ward receiving a triaged patient with Marburg hemorrhagic fever–compatible symptoms.
20] and, at times, the nonavailability of on-site testing. Clinical
case deﬁnitions for MHF determine whether clinicians take a
sample for diagnostic testing and inﬂuence triage decisions.
Clinical case deﬁnitions were developed by the World Health
Organization (WHO) during the Durba and Watsa outbreak
that were based on the Ebola hemorrhagic fever (EHF) case
deﬁnition. To fulﬁl the WHO-recommended deﬁnition, which
was adapted during the outbreak, a patient must have either
(1) an epidemiological link to an individual potentially infected
with MARV and at least 3 of the following general symptoms:
asthenia, anorexia, myalgia or arthralgia, diarrhea, abdominal
pain, nausea, vomiting, headache, dysphagia, dyspnea, con-
junctivitis, jaundice, and hiccups; or (2) fever plus at least 3
general symptoms; or (3) fever plus unexplained hemorrhage
[21]. A highly sensitive clinical case deﬁnition ensures that
patients with true MHF are isolated and prevented from trans-
mitting MARV to community members; a highly speciﬁc case
deﬁnition ensures that uninfected patients are not placed at
risk of nosocomial infection in the Marburg ward. Until the
Uige outbreak, there were limited opportunities to test the
validity of individual patient characteristics, symptomology,
and contact history as diagnostic criteria of MHF.
The Uige outbreak is the largest recorded outbreak of MHF
to date. Most cases originated from Uige City, a municipality
of ∼180,000 inhabitants. Theinitialinvestigation,conﬁrmation,
and notiﬁcation of the outbreak are described elsewhere[3,22–
24]. During the outbreak, Uige Provincial Hospital’s Marburg
ward received patients with MHF-compatible symptoms iden-
tiﬁed by surveillance teams operating in the community, health
care workers operating a triage system elsewhereinthehospital,
and patient self-referral (Figure 1). On presentation at the hos-
pital, patientswithsuspectedMHFwereexaminedbyaclinician
and had blood specimens taken for onsite laboratory testing
by the National Microbiology Laboratory–Public Health
Agency of Canada, who provided results within 4–6 h. A lab-
oratory in Luanda, Angola, operated by the US Centers for
Disease Control and Prevention, subsequently conﬁrmed all
Marburg-related laboratory results.
Patients with positive PCR results were classiﬁed as con-
ﬁrmed cases and admitted to the Marburg ward. Patients with
negative PCR results who had a blood sample obtained more
than 2–3 days after the onset of symptoms were classiﬁed as
having non-MHF cases and were reexamined for an alternative
illness. If a patient with negative PCR results had samples ob-
tained 2–3 days or less after symptom onset, an additional
sample was obtained for testing 24–48 h later. Patients with a
positive result were admitted to the Marburg ward, and those
with a second negative PCR result were classiﬁed as not hav-
ing MHF.
The objectives of this study were to: (1) evaluate the diag-
nostic validity of individual patient clinicalandepidemiological
characteristics and WHO-recommended case deﬁnitions for
MHF and (2) develop a data-derived diagnostic algorithm for
MHF that improves theWHO-recommendeddeﬁnitions.Anal-
ysis of the patient data was approved by the Ethical Review
Boards of Me ´decins Sans Frontie `res, London School ofHygieneMarburg Hemorrhagic Fever • JID 2010:201 (15 June) • 1911
and Tropical Medicine, and by representatives of the Angolan
Ministry of Health and the Angolan Armed Forces in Uige.
METHODS
Study population and variables. Patients with suspected
MHF who presented at the Uige Provincial Hospital from
March through July 2005 and who had MARV PCR results
were included in this study. Data were collected on patient
demographic characteristics, contact history, clinical symptoms
at hospital admission, and MARV PCR results. Demographic
variables included sex, age, residence,ethnicity,andoccupation.
Contact history with an individual potentially infected with
MARV (deﬁned as a person, alive or deceased, who met the
criteria for an MHF operational case deﬁnition) was restricted
to contact 2–21 days before symptom onset, which is the pu-
tative incubation period for MHF. Contact was categorized into
3 groups: (1) indirect contact comprised sleeping in the same
household as an individual potentially infected with MARV or
touching objects used by the individual (eg, cutlery); (2) direct
contact comprised contact with the body or body ﬂuids (in-
cluding breast milk) of an individual potentially infected with
MARV; (3) contact during funeral practices included direct
contact with the corpse of an individual potentially infected
with MARV, the corpse’s body ﬂuids, or potentially contami-
nated objects(eg,soiled clothingormattresses).Funeralcontact
was categorized separately, because the intensity and duration
of contact may have differed from that for contact with live
patients. Because contact categories were not mutually exclu-
sive, patients were categorized according to their highest level
of contact. For example, patients with direct and indirect con-
tact were classiﬁed as having direct contact; those with funeral
and other contact were assigned to funeral contact. Individuals
with direct or funeral contact were deﬁned as having an epi-
demiological link.
The outcome variable was MHF conﬁrmation by PCR. Con-
ﬁrmation was obtained by 1-step reverse-transcriptase PCR as-
say targeting the polymerase, glycoprotein, and nucleoprotein
genes of the MARV genome. Ampliﬁcation was run on a
SmartCycler (Cepheid) using SYBR Green incorporation and
subsequent melt curve analysis [25, 26; A. Grolla and H. Feld-
mann, unpublished data]. A sample was considered to be pos-
itive when at least 2 assays resulted in positive ampliﬁcation.
When possible, PCR products were sequence-conﬁrmed at the
National Microbiology Laboratory–Public Health Agency of
Canada.
Data analysis. Data were entered into Microsoft Excel and
analyzed with Stata, version 9 (StataCorp). Clinical and contact
characteristics were cross-tabulated against PCR results to ob-
tain their sensitivity and speciﬁcity. Each element of the WHO-
recommended clinical case deﬁnition was assessed, together
with 2 overall WHO deﬁnitions: (1) individuals who had any
of the 3 elements of the case deﬁnition (including an epide-
miological link) or (2) individuals with either of the 2 clinical
deﬁnitions (fever plus at least 3 general symptoms or fever plus
unexplained hemorrhage). The latter deﬁnition was assessed
because it may be employed when information about epide-
miological contact is unavailable.
Based on clinical and contact characteristics and using the
method of Quigley et al [27], alternative diagnostic algorithms
for MHF were identiﬁed using logistic regression. Using PCR
results as the outcome, univariable odds ratios (ORs) were
obtained for each characteristic. Variables with an OR of 1.5
or 0.75 and a P value of !.2 on univariable analysis were
added sequentially to a multivariable logistic model starting
with the variable with the strongest association and were re-
tained if they maintained a P value of !.1. Two separate mul-
tivariable models were created; the ﬁrst was basedonsymptoms
only, whereas the second included symptoms and contact var-
iables, thus simulating a situation where a surveillance system
delivers this information.
The log ORs for the characteristics in the ﬁnal models were
used to assign an overall score for each individual by summing
the values of the log ORs for each characteristic that the in-
dividual possessed. A range of score cutoffs were assessed to
identify the cutoff that maximized sensitivity and speciﬁcity of
the diagnosis by best dividing individuals with a PCR-positive
result (score greater than or equal to the cutoff value) from
those with a PCR-negative result (score less than the cutoff
value) [27]. New case deﬁnitions were constructed using these
cutoff values.
RESULTS
Description of study population. Table 1 shows the demo-
graphic characteristics of the 102 patients with suspected MHF
who presented at the Uige Provincial Hospital from March
through July 2005. An MHF diagnosis was conﬁrmed by PCR
in 41 patients. Three-quarters of patients with conﬁrmed cases
were female, nearly one-third were housewives, 14.6% were
children !5 years of age, and 13.2% were health care workers.
The majority of patients with conﬁrmed MHF came from Uige
urban or suburban residential areas.
Univariable analyses. Table 2 shows the sensitivity, spec-
iﬁcity,and univariableORofcontacthistory,clinicalsymptoms,
and WHO-recommended case deﬁnitions for a valid PCR-pos-
itive diagnosis. Compared with patients without a reported
contact history, the odds of having positive PCR results were
6.88 times greater for patients with indirect contact with an
individual with a suspected case of MHF, 11 times greater for
patients with direct contact, and 38.5 times greater for patients
with funeral contact. Having an epidemiological link (direct or
funeral contact) had moderate sensitivity (67%) and high spec-
iﬁcity (86%) for a PCR-positive diagnosis.1912 • JID 2010:201 (15 June) • Roddy et al
Table 1. Demographic Characteristics of Patients
with Suspected Marburg Hemorrhagic Feverwho Pre-
sented at the Uige Provincial Hospital (Uige, Angola),
March–July 2005, by Polymerase Chain Reaction
(PCR) Result.
Variable
No. (%) of patients,
by PCR results
Positive
(n p 41)
Negative
(n p 61)
Sex
Male 10 (24.4) 27 (44.3)
Female 31 (75.6) 34 (55.7)
Age
!5 Years 6 (14.6) 17 (27.9)
5–14 Years 2 (4.9) 4 (6.6)
15–29 Years 12 (29.3) 13 (21.3)
30–39 Years 13 (31.7) 15 (24.6)
 40 Years 8 (19.5) 12 (19.7)
Ethnicity
a
Other 3/34 (8.8) 12/49 (24.5)
Kikongo 31/34 (91.2) 37/49 (75.5)
Occupation
a
Student 12/38 (31.6) 20/55 (36.4)
Housewife 12/38 (31.6) 15/55 (27.3)
Other adult worker 9/38 (23.7) 15/55 (27.3)
Health care worker 5/38 (13.2) 5/55 (9.1)
Residence
a
Urban/suburban 34/39 (87.2) 50/56 (89.3)
Rural 5/39 (12.8) 6/56 (10.7)
a Data missing for some individuals
Of the general symptoms at hospital admission, myalgia or
arthralgia had the strongest association with PCR conﬁrma-
tion, with a sensitivity and speciﬁcity of 63% and 66%, re-
spectively. Conjunctivitis, hiccups, and jaundice had high spec-
iﬁcity (90%) but poor sensitivity. Conversely, fever and as-
thenia had high sensitivity but poor speciﬁcity. Among the
hemorrhagic symptoms, bleeding at the injection site was
most strongly associated with PCR conﬁrmation, with high
speciﬁcity (97%) but low sensitivity (12%).
The WHO-recommended case deﬁnition requiring an epi-
demiological link and 3 general symptoms had high speci-
ﬁcity (93%) but low sensitivity (54%); decreasing the number
of required general symptoms to 2 failed to improve sensitivity
(Table 2). The WHO-recommended case deﬁnition that was
based on clinical criteria alone had lower speciﬁcity (43%),
compared with that of deﬁnitions requiring an epidemiological
link, but higher sensitivity (73%). Combining all elements of
the WHO-recommended case deﬁnition (epidemiological link
plus at least 3 generalsymptoms,feverplus3generalsymptoms,
or fever plus hemorrhage), as practiced during the outbreak,
yielded a sensitivity of 79% and aspeciﬁcityof39%forcorrectly
identifying patients with PCR-conﬁrmed MHF.
Multivariable analyses. Variables eligible for the multivar-
iable models were myalgia or arthralgia, anorexia, asthenia, any
hemorrhage, bleeding at an injection site, bloody gingivitis and,
for model 2, an epidemiological link. In the ﬁrst model, com-
prising only clinical characteristics ( ), no variables re- n p 102
mained associated with a PCR-positive result at the level P ! .1
after adjusting for other variables (data not shown). Table 3
shows the results for the model that included the epidemio-
logical link variable for the 95 patients with available data.
Because bleeding at an injection site and bloody gingivitis were
components of any form of hemorrhage, all 3 variables could
not be used in the same model. Therefore,2separatesubmodels
were built: Model 2a assessed any form of hemorrhage, and
Model 2b assessed the 2 individual hemorrhage variables.
In both Models 2a and 2b, an epidemiological link was most
strongly associated with a PCR-positive result (adjusted ORs
of 14.29 and 13.47, respectively; ), and myalgia or ar- P ! .001
thralgia remained a predictor for a valid MHF diagnosis, with
adjusted ORs of 2.66 and 2.81, respectively. Also retained in
the ﬁnal models were any hemorrhage in Model 2a (OR, 2.59;
) and bleeding at injection site in Model 2b (OR, 6.7; P p .09
). P p .05
The log ORs, listed inTable3,wereusedtoderiveindividuals’
scores. After examining a range of score cutoff values (Table
4), we identiﬁed a cutoff value of 1.93 for Model 2a, which
produced a diagnostic algorithm with equivalent sensitivity
(79%) and appreciably higher speciﬁcity than all combinations
of WHO-recommended case deﬁnitions (73% vs 39%; P !
, by exact McNemar test). Using this cutoff value, an in- .001
dividual who presented at the hospital would be considered to
have MHF if he or she had either (1) an epidemiological link
or (2) both myalgia or arthralgia and any hemorrhage. Model
2b gave a sensitivity of 74% (95% conﬁdence interval [CI],
58%–87%) and speciﬁcity of 86% (95% CI, 74%–94%) when
a cutoff of 2.60 was used. This resulted in a case deﬁnition
similar to that in Model 2a, whereby an individual required
either (1) an epidemiological link or (2) both myalgia or ar-
thralgia and bleeding from the injection site (data not shown).
Because indirect contact with a case of suspected MHF was
also associated with increased odds of positive PCR results, we
conducted a sensitivity analysis that recreated the epidemio-
logical link variable to include all contact categories (direct,
funeral, and indirect) and assessed this new variable in the
diagnostic algorithm. Both the sensitivity and the speciﬁcity of
this new variable were 79% on univariable analysis. The log
OR of the new variable in Model 2a was 3.64, and the optimum
balance of sensitivity and speciﬁcity was obtained using a cutoff
value just below this value (data not shown). This gave a case
deﬁnition whereby an individual was considered to have MHF
if he or she had any contact (direct, funeral, or indirect) with
a suspected case, irrespective of any other clinical symptomsMarburg Hemorrhagic Fever • JID 2010:201 (15 June) • 1913
or signs (sensitivity, 79% [95% CI, 64%–91%]; speciﬁcity, 79%
[95% CI, 66%–88%]).
DISCUSSION
We used patient epidemiological and clinical data on presen-
tation to the hospital during the 2005 Uige MHF outbreak and
MARV-PCR results to assess the sensitivity and speciﬁcity of
epidemiological and clinical indicators and WHO-recom-
mended case deﬁnitions. Our ﬁndings indicate that, for indi-
viduals who presented at the hospital, a history of contact with
an individual potentially infected with MARV was highly pre-
dictive of MHF, whereas much of the clinical data were less
helpful. The disease hallmark, fever in combination with 3
general symptoms or with hemorrhage, was only weakly as-
sociated with PCR conﬁrmation of MHF. Of the generalized
symptoms, myalgia or arthralgia was the strongest predictor of
MHF but had intermediate sensitivity and speciﬁcity. The use-
fulness of this symptom as an MHF predictor is limited by its
subjectivity and the difﬁculty in assessing it in young children.
The frequency of clinical manifestations experienced by in-
dividuals with conﬁrmed MHF at admission to the Marburg
ward in Uige corresponds to those documented during the
Durbaand Watsaoutbreak[17].Becauseourdataonlycaptured
MHF clinical manifestations at hospital admission, symptoms
that typically manifest later in the course of disease (eg, nausea
and vomiting, abdominal pain, and diarrhea) were reported
relatively infrequently (in !50% of cases), and late-onset symp-
toms (eg, hiccups, jaundice, and conjunctivitis) were observed
in !20% of patients.
In ﬁlovirus hemorrhagic fever (FHF), hemorrhagic symp-
toms typically develop late in the course of disease [17, 28].
Only one-half of the patients who were later conﬁrmed to have
MHF presented with hemorrhagic symptoms at hospital ad-
mission. Epistaxis and hematemesis were observed in !10% of
patients with conﬁrmed MHF and bleeding from gums or
bloody diarrhea in !20%. Bleeding from an injection site had
high speciﬁcity; its low sensitivity may be explained by its de-
pendence on having received an injection. Although hemor-
rhage from natural oriﬁces can be caused by local and systemic
disturbances, bleeding from an injection site is rare without a
systemic coagulation disorder, as may occur with FHF [29] but
not, typically, in certain diseases for which FHFcanbemistaken
(eg, typhoid and shigellosis). The high speciﬁcity of this char-
acteristic suggests that a bedside clotting test could help to
differentiate late-stage FHF from other diseases that cause
bleeding when speciﬁc on-site virological tests are unavailable.
Because in vitro coagulopathy may precede spontaneous bleed-
ing, a bedside clotting test could also help to diagnose FHF
before hemorrhage manifests. Further study is warranted.
The WHO-recommended case deﬁnition integrating infor-
mation on prior contact and general clinical symptoms had a
sensitivity of 54%, thus failing to identify many MHF-infected
individuals. Notably, sensitivity was not improved by reducing
the number of required general symptoms from 3 to 2. The
combination of WHO-recommended case deﬁnitions incor-
porating epidemiological criteria and clinical data on fever,
general symptoms, and hemorrhage achieved reasonable sen-
sitivity (79%) but low speciﬁcity (39%).
We explored alternative diagnostic algorithms for MHF that
might improve sensitivity and/or speciﬁcity, compared with the
WHO-recommended case deﬁnitions.Ourﬁndingssuggestthat
a case deﬁnition that is based on the presence of an epide-
miological link or the combination of myalgia or arthralgia and
any hemorrhage could potentially serve as a reasonable alter-
native to currently recommended MHF case deﬁnitions when
assessing patients who present to the hospital. In our study
population, this new case deﬁnition maintained the sensitivity
of the all-combined WHO case deﬁnition (79%) but had in-
creased speciﬁcity (73% vs 39%). This underlines the impor-
tance of a community surveillance system that provides epi-
demiological data on prior patient contacts and of integrating
epidemiological data into the clinical assessmentwhendeciding
on isolation or PCR testing. Sensitivity analyses suggested that
a higher speciﬁcity (79%) could be obtained by incorporating
all contact (including indirect contact) into the epidemiological
link variable and using this variable alone for an operational
MHF case deﬁnition. This may be attributable to misclassiﬁ-
cation of direct contact as indirect contact.
We found that the age and sex distribution of our study
population differed from that reported in the only other major
MHF outbreak. The Durba and Watsa outbreak was driven by
repeated primary transmission to adult male mining workers
[15], whereas the Uige outbreak was fuelled by nosocomial and
secondary transmission to caregivers in the community [30].
Caregiving is traditionally a female role in sub-Saharan Africa,
which may explain the dominance of females among patients
with conﬁrmed MHF (75.6%). A similar pattern was found for
EHF in Kikwit, Democratic Republic of the Congo [28, 31].
Children !5 years of age accounted for 15% of patients with
conﬁrmed MHF in Uige, which contrasts with previous reports
of infrequent FHF in young children [32, 33]. The children in
Uige were possibly infected while using health services during
the early stages of the outbreak [34]. Without a detailed epi-
demiological description of the outbreak, it is difﬁcult to in-
terpret the sex and age distribution.
One limitation of this study is its small sample size. We could
not fully replicate Quigley’s approach, which involves dividing
the database into two subsets, using one subset for developing
the case deﬁnition and the other for its validation. The sample
size also limited statistical power to detect associations be-
tween many variables and PCR results positive for MARV and
yielded large conﬁdence intervals for sensitivity and speciﬁcity1914
Table 2. Sensitivity, Speciﬁcity, and Crude Odds Ratios (ORs) for Contact History, Clinical Symptoms and
World Health Organization (WHO)–Recommended Case Deﬁnitions of Marburg Hemorrhagic Fever (MHF)
among Polymerase Chain Reaction (PCR)–Positive and PCR-Negative Patients with Suspected MHF who
Presented at the Uige Provincial Hospital (Uige, Angola), March–July 2005.
Variable
No. (%) of patients,
by PCR results
Sensitivity, %
(95% CI)
Speciﬁcity, %
(95% CI) OR (95% CI) P
Positive
(n p 41)
Negative
(n p 61)
Contact history
a
None 8/39 (20.5) 44/56 (78.6) 1.00
Indirect 5/39 (12.8) 4/56 (7.1) … … 6.88 (1.35–35.08) .007
Direct 12/39 (30.8) 6/56 (10.7) 11.00 (2.62–46.15) !.001
Funeral 14/39 (35.9) 2/56 (3.6) 38.50 (4.2–352.1) !.001
Contact history/epidemiolog-
ical link
a,b
Yes 26/39 (66.7) 8/56 (14.3) 67 (50–81) 86 (74–94) 12.00 (3.64–39.61) !.001
No 13/39 (33.3) 48/56 (85.7) 1.00
Fever
Yes 35 (85.4) 49 (80.3) 85 (71–94) 20 (11–32) 1.43 (0.49–4.20) .51
No 6 (14.6) 12 (19.7) 1.00
Asthenia
Yes 34 (82.9) 41 (67.2) 83 (68–93) 33 (21–46) 2.37 (0.88–6.40)
No 7 (17.1) 20 (32.8) 1.00 .08
Anorexia
Yes 27 (65.9) 29 (47.5) 66 (49–80) 53 (39–65) 2.13 (0.92–4.91) .07
No 14 (34.2) 32 (52.5) 1.00
Myalgia or arthralgia
Yes 26 (63.4) 21 (34.4) 63 (47–78) 66 (52–77) 3.30 (1.39–7.85) .004
No 15 (36.6) 40 (65.6) 1.00
Diarrhea
Yes 19 (46.3) 24 (39.3) 46 (31–63) 61 (47–73) 1.33 (0.59–2.98) .49
No 22 (53.7) 37 (60.7) 1.00
Abdominal pain
Yes 15 (36.6) 22 (36.1) 37 (22–53) 64 (51–76) 1.02 (0.45–2.34) .96
No 26 (63.4) 39 (63.9) 1.00
Nausea and vomiting
Yes 14 (34.2) 20 (32.8) 34 (20–51) 67 (54–79) 1.06 (0.46–2.47) .89
No 27 (65.9) 41 (67.2) 1.00
Headache
Yes 13 (31.7) 21 (34.4) 32 (18–48) 66 (52–77) 0.88 (0.38–2.07) .78
No 28 (68.3) 40 (65.6) 1.00
Dysphagia
Yes 11 (26.8) 13 (21.3) 27 (14–43) 79 (66–88) 1.35 (0.53–3.43) .52
No 30 (73.2) 48 (78.7) 1.00
Conjunctivitis
Yes 7 (17.1) 6 (9.8) 17 (7–32) 90 (80–96) 1.89 (0.58–6.17) .28
No 34 (82.9) 55 (90.2) 1.00
Dyspnea
Yes 5 (12.2) 13 (21.3) 12 (4–26) 79 (66–88) 0.51 (0.17–1.59) .24
No 36 (87.8) 48 (78.7) 1.00
Hiccups
Yes 2 (4.9) 3 (4.9) 5 (1–17) 95 (86–99) 0.99 (0.16–6.27) .99
No 39 (95.1) 58 (95.1) 1.00
Jaundice
Yes 1 (2.4) 4 (6.6) 2 (0–13) 93 (84–98) 0.36 (0.04–3.38) .35
No 40 (97.6) 57 (93.4) 1.00
Any hemorrhage
Yes 21 (51.2) 22 (36.1) 51 (35–67) 64 (51–76) 1.86 (0.82–4.22) .13
No 20 (48.8) 39 (63.9) 1.00
Nonmenstrual vaginal bleed
c
Yes 6 (20.0) 3 (9.4) 20 (8–39) 91 (75–98) 2.42 (0.53–11.0) .241915
Table 2. (Continued.)
Variable
No. (%) of patients,
by PCR results
Sensitivity, %
(95% CI)
Speciﬁcity, %
(95% CI) OR (95% CI) P
Positive
(n p 41)
Negative
(n p 61)
No 24 (80.0) 29 (90.6) 1.00
Bloody gingivitis
Yes 7 (17.1) 4 (6.6) 17 (7–32) 93 (84–98) 2.93 (0.78–11.0) .09
No 34 (82.9) 57 (93.4) 1.00
Bloody diarrhea
Yes 7 (17.1) 14 (22.9) 17 (7–32) 77 (65–87) 0.69 (0.25–1.91) .47
No 34 (82.9) 47 (77.1) 1.00
Bleeding at injection site
Yes 5 (12.2) 2 (3.3) 12 (4–26) 97 (89–100) 4.10 (0.73–23.0) .08
No 36 (87.8) 59 (96.7) 1.00
Hematemesis
Yes 3 (7.3) 7 (11.5) 7 (2–20) 89 (78–95) 0.61 (0.15–2.53) .49
No 38 (92.7) 54 (88.5) 1.00
Epistaxis
Yes 2 (4.9) 1 (1.6) 5 (1–17) 98 (91–100) 3.08 (0.26–35.9) .34
No 39 (95.1) 60 (98.4) 1.00
Hemoptysis
Yes 0 (0.0) 1 (1.6) 0 (0–9) 98 (91–100) … …
No 41 (100.0) 60 (98.4)
Deﬁnition 1: epidemiological
link and 3 general
symptoms
a
Yes 21/39 (53.9) 4/56 (7.1) 54 (37–70) 93 (83–98) 15.2 (3.7–62.1) !.001
No 18/39 (46.2) 52/56 (92.9) 1.00
Deﬁnition 2: epidemiological
link and 2 general
symptoms
a
Yes 21/39 (53.9) 5/56 (8.9) 54 (37–70) 91 (80–97) 11.9 (3.3–43.2) !.001
No 18/39 (46.2) 51/56 (91.1) 1.00
Deﬁnition 3: fever 3
symptoms
Yes 28 (68.3) 33 (54.1) 68 (52–82) 46 (33–59) 1.83 (0.79–4.24) .15
No 13 (31.7) 28 (45.9) 1.00
Deﬁnition 4: Fever and
hemorrhage
Yes 18 (43.9) 17 (27.9) 44 (28–60) 72 (59–83) 2.03 (0.87–4.73) .10
No 23 (56.1) 44 (72.1) 1.00
Any WHO case deﬁnition
d
(clinical criteria only)
Yes 30 (73.2) 35 (57.4) 73 (57–86) 43 (30–56) 2.03 (0.85–4.85) .11
No 11 (26.8) 26 (42.6) 1.00
Any WHO case deﬁnition
a,e
(all elements included)
Yes 31/39 (79.5) 34/56 (60.7) 79 (64–91) 39 (26–53) 2.5 (0.95–6.61) .05
No 8/39 (20.5) 22/56 (39.3) 1.00
NOTE. CI, conﬁdence interval.
a Data missing for some individuals
b Epidemiological link was deﬁned as direct contact with an individual potentially infected with MHF or his or her body ﬂuids
or direct contact during funeral practices.
c Nonmenstrual vaginal bleeding includes females only ( ). np 62
d Deﬁned as corresponding to WHO deﬁnition 3 or 4.
e Deﬁned as corresponding to WHO deﬁnition 1, 3, or 4.1916 • JID 2010:201 (15 June) • Roddy et al
Table 3. Adjusted Odds Ratios (ORs) for Characteristics As-
sociated with Marburg Hemorrhagic Fever Conﬁrmation in 95
Patients at Uige Provincial Hospital for Whom Epidemiological
Data were Available
Variable
Adjusted OR
a (95%
conﬁdence interval) P Log OR
Model 2a
Epilink
Yes 14.29 (4.62–44.16) !.001 2.66
No 1.00
Myalgia or arthralgia
Yes 2.66 (0.96–7.41) .06 0.98
No 1.00
Any hemorrhage
Yes 2.59 (0.87–7.71) .09 0.95
No 1.00
Model 2b
Epilink
Yes 13.47 (4.60–39.46) !.001 2.60
No 1.00
Myalgia or arthralgia
Yes 2.81 (1.00–7.85) .05 1.03
No 1.00
Bleeding at injection site
Yes 6.70 (0.97–46.00) .05 1.90
No 1.00
a Adjusted for other variables in the model.
Table 4. Possible Combinations of Predictors of Marburg Hemorrhagic Fever Retained in Final Logistic Regression Model 2a (Epi-
demiological Link, Myalgia or Arthralgia, Any Hemorrhage): Sums of Log Odds Ratios (ORs), Cutoff Values, Sensitivity, and Speciﬁcity
Variable Epi link
Epi link plus
any hemorrhage
Epi link plus
myalgia or arthralgia
Epi link plus
myalgia or
arthralgia
plus any
hemorrhage
Myalgia or
arthralgia
plus any
hemorrhage
Myalgia or
arthralgia
Any
hemorrhage
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
Sum of log ORs 2.66 3.61 3.64 4.59 1.93 0.98 0.95
Cutoff value
4.59 … … … X … … … 31 (17–48) 98 (90–100)
3.64 … … X X … … … 46 (30–63) 95 (85–99)
3.61 … X X X … … … 49 (32–65) 95 (85–99)
2.66 X X X X … … … 67 (50–81) 86 (74–94)
1.93 X X X X X … … 79 (64–91) 73 (60–84)
0.98 X X X X X X … 87 (73–96) 54 (40–67)
0.95 X X X X X X X 95 (83–99) 29 (17–42)
NOTE. CI, conﬁdence interval; Epi, epidemiological; X, possible combination.
estimates. Because Uige was a major outbreak, this limitation
can possibly only be overcome by pooling data across com-
parable outbreaks and/or testing our diagnostic algorithm in
future outbreaks.
Predominant transmission routes vary among outbreaks,
which makes it difﬁcult to develop a universal FHF case def-
inition. Our proposed case deﬁnition, which was developed
using data from an outbreak fueled by secondary transmis-
sion, may be less sensitive during an epidemic that is driven
by multiple primary introductions. However, a case deﬁnition
that emphasizes the role of epidemiological contact is likely to
be relevant for most FHF outbreaks, because those that are
fuelled by primary transmission are infrequent.
Detailed data were not available for all of the MHF cases
that were declared to have occurred by the WHO and the
Angolan Ministry of Health. The hospital-based data collection
may have inﬂuenced the sex and age distribution, frequency of
symptoms observed, and the generalizability of our ﬁndings.
Many ill individuals avoided seeking hospital care because of
reports of numerous deaths occurring at the hospital. Individ-
uals with more-serious symptoms that necessitated hospitali-
zation may be overrepresented in our study.
In contrast to the Durba and Watsa outbreak, in which the
onset, duration, and symptom patterns that developed during
hospitalization were collected, only presenting symptoms were
recorded in Uige patients. This is regrettable, because a hospital
is an ideal location for collecting clinical data. As in previous
FHF outbreaks, the clinical picture of hospitalized patients with
MHF in Uige, including any response to treatment, is incom-
plete because of poor clinical documentation. This highlights
the need for (1) collection of high-quality clinical data on these
poorly understood diseases by the organizations that provide
clinical care to patients with FHF and (2) agreement, together
with the WHO, whose mandate it is to set standards, on stan-
dardized clinical data forms and their implementationinfuture
outbreaks. In the meantime, we suggest using the clinical data
form proposed by Colebunders et al [17].
CONCLUSIONS
During an epidemic of a highly lethal disease, such as MHF,
care of severely ill individuals often takes precedence over clin-
ical data collection efforts. Despite the challenges, organizationsMarburg Hemorrhagic Fever • JID 2010:201 (15 June) • 1917
that respond to an FHF outbreak must work collaboratively to
collect high-quality clinical and epidemiological data. The cur-
rent MHF case deﬁnitions recommended by the WHO were
useful for clinicians who responded to the Uige outbreak but
could possibly be improved. During the outbreak, FHF-expe-
rienced clinicians encountered some potentially infected indi-
viduals whose presenting criteria did not match a WHO-rec-
ommended case deﬁnition, and those clinicians decided to
proceed with a diagnostic test or assess the individual for an
alternative illness. We believe that clinicians should continue
to use their discretion in these circumstances.
This article suggests possible alternatives to the current MHF
case deﬁnitions when deciding on isolation or PCR testing and
highlights the necessity of collecting high-quality clinical and
epidemiological data during outbreaks. Improved data on pa-
tient characteristics, symptoms, and contact history would fur-
ther our knowledge about FHF epidemiological patterns and
may help to reﬁne WHO-recommended FHF case deﬁnitions.
This, together with treatment modality data, will improve out-
break response.
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